Cigna subsidiary Evernorth Health Services will automate prior authorizations for GLP-1 weight-loss drugs under a new program ...

The agreements cap monthly out-of-pocket costs for Zepbound and Wegovy at $200 and more deeply discount the drugs for ...

The Cigna Group (NYSE:CI)’s Evernorth division has announced a new deal with Novo Nordisk and Eli Lilly that will limit ...

The new weight-loss option will cut what the plan sponsors pay as well as what the patients pay, Cigna’s PBM Evernorth says.

Cigna’s (NYSE:CI) health services arm, Evernorth, has launched a pharmacy benefit program that caps out-of-pocket costs at $200 per month for patients using the weight-loss drugs - Wegovy from Novo ...

Cigna’s pharmacy benefits unit Evernorth said the deal will bring prices down for employers and their workers.

The health services arm of The Cigna Group CI, Evernorth, recently introduced a pharmacy benefit offering designed to enhance ...

Cigna also announced a specialized GLP-1 pharmacy, which will soon go live for patients. Evernorth Health Services introduced EncircleRx, which includes a financial guarantee that protects plans ...

Evernorth said that through direct negotiations with Novo Nordisk and Eli Lilly, patients’ monthly copay costs for Wegovy ...

Novo Nordisk's insulin aspart franchise is a DKK 10.6 billion ($1.5 billion) business worldwide ... of a mandatory $35 monthly insulin copay cap for Medicare. While a few years ago, the loss ...

Cigna on Wednesday said it negotiated with Novo Nordisk and Eli Lilly to secure deeper GLP-1 drug discounts for employers ...